Linda Y. Wu

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 112 citations · Full text

Medicine, Oncology, Pharmacology +6

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio et al. · Cancers · 2022 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells

Linda Y. Wu, Uday Bhanu Maachani, Melanie Schweitzer et al. · Translational Oncology · 2017 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi et al. · Liver International · 2022 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +15